European Journal of Clinical Pharmacology

, Volume 11, Issue 3, pp 193–198 | Cite as

Agranulocytosis during treatment with clozapine

  • J. Idänpään-Heikkilä
  • E. Alhava
  • M. Olkinuora
  • I. P. Palva
Originals

Summary

Within six months of the introduction of the new antipsychotic drug clozapine in Finland, 17 cases of neutropenia or agranulocytosis were recorded amongst about 3000 patients treated. Agranulocytosis was fatal in eight patients, and in addition, two patients developed thrombocytopenia, and one patient leukaemia. As additional cases might well have been overlooked as banal infections, the risk of developing agranulocytosis during clozapine treatment was at least 0.5%. Impaired elimination of the drug or increased susceptibility of granulocyte precursors to clozapine, possibly due to some inherited characteristic, might explain the high incidence of complications.

Key words

clozapine agranulocytosis adverse reaction side effect haematological effect psychopharmacological agent neuroleptics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gross, H., Lagner, E.: Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Benzodiazepingruppe. Wien. med. Wschr.116, 814–818 (1966)Google Scholar
  2. 2.
    Angst, J., Jaenicke, U., Padrutt, A., Scharfetter, Ch.: Ergebnisse eines Doppelblindversuches von HF 1854 im Vergleich zu Levomepromazin. Pharmakopsychiat.4, 192–200 (1971)Google Scholar
  3. 3.
    Gross, H., Lagner, E.: Das Neuroleptikum 100–129/HF-1854 (Clozapin) in der Psychiatrie. Pharmakopsychiat.4, 220–226 (1970)Google Scholar
  4. 4.
    Griffith, R. W., Saameth, K.: Clozapine and agranulocytosis. Lancet1975 II, 657Google Scholar
  5. 5.
    Niskanen, P., Achté, K. A., Jaskari, M., Karesoja, M., Melsted, B., Nilsson, L., Routavaara, M., Tamminen, T., Tienari, P., Vogel, G.: Result of a comparative double-blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients. Psychiat. Fennica1, 307–312 (1974)Google Scholar
  6. 6.
    Idänpään-Heikkilä, J., Alhava, E., Olkinuora, M., Palva, J.: Clozapine and agranulocytosis. Lancet1975 II, 611.Google Scholar
  7. 7.
    Pisciotta, A. V.: Effects of phenothiazines on leukocytes. In: Drugs and hematologic reactions (ed. N. V. Dimitrov, J. H. Nodie) p. 233. New York: Grune and Stratton 1974Google Scholar
  8. 8.
    Palva, L. P., Mustala, O. O.: Drug-induced agranulocytosis with special reference to aminophenazone. Acta med. scand.187, 109–112 (1970)Google Scholar
  9. 9.
    Nieweg, H. O.: Drug induced diseases as seen by a haematologist. In: Drug-induced diseases (ed. L. Meyler, H. M. Peck) p. 323. Amsterdam: Excerpta Medica 1972Google Scholar
  10. 10.
    Blum, A., Mauruschat, W.: Über Temperaturanstiege unter der Therapie mit Psychopharmaka. Jugoslav. Symposium über Psychopharmakologie, Zagreb 1969Google Scholar
  11. 11.
    Pisciotta, A. V.: Studies on agranulocytosis. VII. Limited proliferative potential of chlorpromazine sensitive patients. J. Lab. clin. Med.65, 240–247 (1965)Google Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • J. Idänpään-Heikkilä
    • 1
  • E. Alhava
    • 1
  • M. Olkinuora
    • 1
  • I. P. Palva
    • 1
  1. 1.National Board of HealthHelsinkiFinland

Personalised recommendations